Wanbury Limited, a pharmaceutical company listed on both the NSE and BSE, has announced the upcoming launch of two new products this month: Wanbury C-RED, a branded formulation targeting the gynaecology segment, and Ketamine Hydrochloride, an active pharmaceutical ingredient (API).
At 2.18 pm today, Wanbury Limited’s shares were trading at ₹266.01, up by ₹25.09 or 10.41 per cent on the NSE.
Wanbury C-RED is a liposomal iron supplement specifically designed to improve haemoglobin levels, particularly during pregnancy. The company claims that this formulation prevents gastric irritation and constipation while ensuring better absorption compared to existing iron salts in the market.
On the other hand, the Ketamine Hydrochloride API, developed in-house by Wanbury’s R&D team, complies with major pharmacopeia standards such as USP and EP. Ketamine is in high demand, exceeding 200 tonnes annually for both human and veterinary markets, and is primarily used to induce sleep before and during surgeries. Wanbury will commence supplying Ketamine this month, starting with exports to European markets.
Established in 1988, Wanbury Limited operates FDA- and EUGMP-approved facilities in Tanuku (Andhra Pradesh) and Patalganga (Maharashtra). The company exports APIs to over 50 countries and has a pan-India presence in the formulation market with products across various therapeutic categories, including cough and cold solutions, gynaecology, orthopaedics, and gastrointestinal treatments.
